Platform Application for Neurodegenerative Diseases
Neurodegenerative Diseases
Pre-clinical/ResearchActive
Key Facts
About ALTUCELL
Altucell is a preclinical-stage biotech company pioneering a microencapsulation platform for cell and regenerative therapies targeting major chronic diseases. Its initial focus appears to be on diabetes, with potential applications in autoimmune and neurodegenerative conditions, aiming to provide long-term therapeutic solutions without chronic immunosuppression. The company is privately held and likely pre-revenue, advancing its research through partnerships and its scientific advisory network. Its value proposition centers on a potentially broadly applicable encapsulation technology designed to protect transplanted cells from immune rejection.
View full company profileTherapeutic Areas
Other Neurodegenerative Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed | Modulo Bio | Discovery |
| PBI-01207 | Phoenix Biotechnology | Pre-clinical |
| Therapeutic Target Discovery Platform | ValtedSeq | Discovery |
| Undisclosed Neurology Program(s) | Base4 | Preclinical |
| OGG1 Activator Program | Luciole Pharmaceuticals | Pre-clinical |
| Lysosome Biology Program | Talisman Therapeutics | Preclinical |
| Microglial Health Program | Talisman Therapeutics | Preclinical |
| HSF1 Activator Program | Sisu Pharma | Pre-clinical |
| Platform-derived candidates | VRG Therapeutics | Pre-clinical |
| Neurodegenerative Biomarkers R&D | Firalis | Development |
| Neurodegeneration Pipeline | Origenis | Preclinical |
| Enhanced Brain Delivery (EBD™) Platform | Acumen Pharmaceuticals | Preclinical |